Default: Drugs

ISSN: 0012-6667

Journal Home

Journal Guideline

Drugs Q1 Unclaimed

Adis International Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drugs is a journal indexed in SJR in Pharmacology (medical) with an H index of 179. It has a price of 3790 €. It has an SJR impact factor of 2,093 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,093.

Drugs focuses its scope in these topics and keywords: review, patients, therapeutic, combined, cellular, complications, concepts, current, development, developmentvonoprazan, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

3790 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Drugs

2,093

SJR Impact factor

179

H Index

148

Total Docs (Last Year)

521

Total Docs (3 years)

9281

Total Refs

5013

Total Cites (3 years)

502

Citable Docs (3 years)

9.44

Cites/Doc (2 years)

62.71

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


review, patients, therapeutic, combined, cellular, complications, concepts, current, development, developmentvonoprazan, differences, dipropionateformoterollisinopriloptimal, azelastinedrugs, doxorubicinsumatriptan, effects, emerging, eosinophilic, administered, established, fibrillation, biofilmbased, agentsthrombolytic, ampakainate, antibacterial, anticoagulants, antifungal, approval, atrial, agents, blockade, breast, btargeting, butylbromidenovel, cancer, cannabidiol, carcinoma,



Best articles by citations

Correction to: Polatuzumab Vedotin: First Global Approval

View more

The Incidence and Antibiotic Susceptibility of Branhamella catarrhalis in Respiratory Infections

View more

Pharmacology and Clinical Experience with Tramadol in Osteoarthritis

View more

Clinical Aspects of Invasive Candidiasis in Paediatric Patients

View more

Current and Emerging Therapeutics for the Management of Endometriosis

View more

Cidofovir

View more

Enalapril

View more

Rifaximin

View more

Enalapril in Hypertension and Congestive Heart Failure

View more

Quinolones in Sexually Transmitted Diseases

View more

Correction to: Secukinumab: A Review in Ankylosing Spondylitis

View more

Basiliximab

View more
SHOW MORE ARTICLES

Quinupristin/Dalfopristin

View more

Treatment of Epilepsy in Pregnancy

View more

Managing Resistance to Anti-HIV Drugs

View more

Otitis Media and Sinusitis in Children Role of Branhamella catarrhalis

View more

Incidence of Branhamella catarrhalis in the Sputa of Patients with Chronic Lung Disease

View more

Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications

View more

Are All Dopamine Agonists Essentially the Same?

View more

Emerging Resistance to Antimicrobial Agents in Gram-Positive Bacteria

View more

Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials

View more

How Does Tinidazole Compare with Metronidazole?

View more

Importance of Drug Enantiomers in Clinical Pharmacology

View more

Gemifloxacin

View more

FAQS